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A B S T R A C T
Background
This is an updated version of the Cochrane Review previously published in the Cochrane Database of Systematic Reviews 2015, Issue 10.
Epilepsy is a common neurological condition, characterised by recurrent seizures. Most people respond to conventional antiepileptic
drugs, however, around 30% will continue to experience seizures, despite treatment with multiple antiepileptic drugs. Sulthiame, also
known as sultiame, is a widely used antiepileptic drug in Europe and Israel. We present a summary of the evidence for the use of
sulthiame as add-on therapy in epilepsy.
Objectives
To assess the efficacy and tolerability of sulthiame as add-on therapy for people with epilepsy of any aetiology compared with placebo
or another antiepileptic drug.
Search methods
For the latest update, we searched the Cochrane Register of Studies (CRS Web), which includes the Cochrane Epilepsy Group’s
Specialized Register and CENTRAL (17 January 2019), MEDLINE Ovid (1946 to January 16, 2019), ClinicalTrials.gov and the
WHO ICTRP Search Portal (17 January 2019). We imposed no language restrictions. We contacted the manufacturers of sulthiame,
and researchers in the field to seek any ongoing or unpublished studies.
Selection criteria
Randomised controlled trials of add-on sulthiame, with any level of blinding (single, double or unblinded) in people of any age, with
epilepsy of any aetiology.
Data collection and analysis
Two review authors independently selected trials for inclusion, and extracted relevant data. We assessed these outcomes: (1) 50% or
greater reduction in seizure frequency between baseline and end of follow-up; (2) complete cessation of seizures during follow-up; (3)
mean seizure frequency; (4) time-to-treatment withdrawal; (5) adverse effects; and (6) quality of life. We used intention-to-treat for
primary analyses. We presented results as risk ratios (RR) with 95% confidence intervals (CIs). However, due to the paucity of trials,
we mainly conducted a narrative analysis.
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Main results
We included one placebo-controlled trial that recruited 37 infants with newly diagnosed West syndrome. This trial was funded by
DESITIN Pharma, Germany. During the study, sulthiame was given as an add-on therapy to pyridoxine. No data were reported for
the outcomes: 50% or greater reduction in seizure frequency between baseline and end of follow-up; mean seizure frequency; or quality
of life. For complete cessation of seizures during a nine-day follow-up period for add-on sulthiame versus placebo, the RR was 11.14
(95% CI 0.67 to 184.47; very low-certainty evidence), however, this difference was not shown to be statistically significant (P = 0.09).
The number of infants experiencing one or more adverse events was not significantly different between the two treatment groups (RR
0.85, 95% CI 0.44 to 1.64; very low-certainty evidence; P = 0.63). Somnolence was more prevalent amongst infants randomised to
add-on sulthiame compared to placebo, but again, the difference was not statistically significant (RR 3.40, 95% CI 0.42 to 27.59; very
low-certainty evidence; P = 0.25). We were unable to conduct meaningful analysis of time-to-treatment withdrawal and adverse effects
due to incomplete data.
Authors’ conclusions
Sulthiame may lead to a cessation of seizures when used as an add-on therapy to pyridoxine in infants with West syndrome, however,
we are very uncertain about the reliability of this finding. The included study was small and had a significant risk of bias, largely due to
the lack of details regarding blinding and the incomplete reporting of outcomes. Both issues negatively impacted the certainty of the
evidence. No conclusions can be drawn about the occurrence of adverse effects, change in quality of life, or mean reduction in seizure
frequency. No evidence exists for the use of sulthiame as an add-on therapy in people with epilepsy outside West syndrome.
Large, multi-centre randomised controlled trials are needed to inform clinical practice, if sulthiame is to be used as an add-on therapy
for epilepsy.
P L A I N L A N G U A G E S U M M A R Y
Sulthiame as add-on therapy for epilepsy
Review question
A team of Cochrane researchers investigated how well sulthiame worked when it was used as an add-on antiepileptic medicine (medicines
that reduce seizures) in people with any type of epilepsy.
Background
Epilepsy is a common neurological (brain) condition that is characterised by repeated seizures. Most people respond well to conventional
antiepileptic medicines, however, about 30% continue to have seizures. These people are said to have drug-resistant epilepsy.
Sulthiame is an antiepileptic drug that is used widely in some European countries and in Israel. Sometimes it is used as an additional
(add-on) antiepileptic medicine for people with epilepsy, alongside an existing antiepileptic medicine.
Main results
Randomised controlled trials produce the most reliable evidence for medicines. The team searched the medical literature for randomised
controlled trials that compared sulthiame as an add-on therapy to add-on placebo (an inactive, dummy drug), or another antiepileptic
medicine.
The researchers found one relevant trial that included 37 infants, aged from three to 15 months, who had a diagnosis of West syndrome,
a type of epilepsy. This trial was funded by DESITIN Pharma (Germany). All infants were started on an antiepileptic medicine,
pyridoxine, three days before they added sulthiame or placebo. The infants’ parents did not know which add-on therapy their children
received. The trial lasted for nine days.
Very uncertain evidence from the trial suggests that sulthiame may stop seizures in people with West syndrome whose seizures do not
stop with pyridoxine. Thirty per cent more infants had their seizures stop when they received add-on sulthiame (6/20 participants)
compared to add-on placebo (0/17 participants). This difference was not statistically significant, mainly because there were so few
infants included in the trial.
The same number of infants experienced one or more adverse effects in both groups (9 in each). More infants experienced somnolence
(drowsiness) when they received add-on sulthiame (4/20), compared to those who received add-on placebo (1/17), but again, this was
not statistically significant.
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The small number of infants in the trial, and its short duration, means that we are not confident that the results are reliable.
Further randomised controlled trials are required before meaningful conclusions can be drawn about how well sulthiame works as an
add-on therapy in West syndrome and other types of epilepsy, and to establish whether it produces any serious unwanted or harmful
effects.
The evidence is current to January 2019.
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S U M M A R Y O F F I N D I N G S F O R T H E M A I N C O M P A R I S O N [Explanation]
Sulthiame add-on compared to placebo for epilepsy
Patient or population: pat ients between 3 to 15 months of age with West syndrome
Setting: inpat ient
Intervention: sulthiame as add-on therapy to pyridoxine
Comparison: placebo as add-on therapy to pyridoxine
Outcomes Anticipated absolute effects∗ (95% CI) Relative effect
(95% CI)
of participants
(studies)
Certainty of the evi-
dence
(GRADE)
Comments
Risk with placebo Risk with Sulthiame
add-on
50% or greater reduc-
tion in seizure fre-
quency
Outcome was not re-
ported by Debus 2004
Complete cessation of
seizures during follow-
up
Follow-up: 9 days
Study population RR 11.14
(0.67 to 184.47)
37
(1 RCT)
⊕©©©
VERY LOWa,b,c
0 per 1,000 0 per 1000
(0 to 0)
Mean seizure fre-
quency
Outcome was not re-
ported by Debus 2004
Time- to- treatment
withdrawal
Outcome was not re-
ported by Debus 2004
Adverse effects: to-
tal number of partici-
pants experiencing one
or more adverse ef-
fects
Follow-up: 9 days
Study population RR 0.85
(0.44 to 1.64)
37
(1 RCT)
⊕©©©
VERY LOWa,b
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529 per 1,000 450 per 1000
(233 to 868)
Adverse effects: som-
nolence
Follow-up: 9 days
Study population RR 3.40
(0.42 to 27.59)
37
(1 RCT)
⊕©©©
VERY LOWa,b,d
59 per 1,000 200 per 1000
(25 to 1000)
Quality of life Outcome was not re-
ported by Debus 2004
*The risk in the intervention group (and its 95% conf idence interval) is based on the assumed risk in the comparison group and the relative effect of the intervent ion (and its
95%CI).
CI: conf idence interval; RR: risk rat io
GRADE Working Group grades of evidence
High certainty: We are very conf ident that the true ef fect lies close to that of the est imate of the ef fect
Moderate certainty: We are moderately conf ident in the ef fect est imate: The true ef fect is likely to be close to the est imate of the ef fect, but there is a possibility that it is
substant ially dif f erent
Low certainty: Our conf idence in the ef fect est imate is lim ited: The true ef fect may be substant ially dif f erent f rom the est imate of the ef fect
Very low certainty: We have very lit t le conf idence in the ef fect est imate: The true ef fect is likely to be substant ially dif f erent f rom the est imate of ef fect
aDowngraded once for risk of bias: Debus 2004 did not describe how blinding was achieved or maintained, and we suspected
report ing bias for the adverse ef fect outcomes.
bDowngraded twice for imprecision: small study populat ion, therefore, the number of events failed to suf f ice opt imal
information size.
cEvidence was not upgraded for ef fect size: normally, the evidence would be upgraded twice when a RR is greater than 5.00,
however, due to the concerns regarding risk of bias and small sample size, we were unable to upgrade the evidence.
dEvidence was not upgraded for ef fect size: normally, the evidence would be upgraded once when a RR is greater than 2.00,
however, due to the concerns regarding risk of bias and small sample size, we were unable to upgrade the evidence.
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B A C K G R O U N D
This review is an update of the previously published review in
the Cochrane Database of Systematic Reviews (Milburn-McNulty
2015).
Description of the condition
Epilepsy is a common neurological condition that is characterised
by recurrent seizures. It has an estimated worldwide prevalence of
between four and 10 per 1000 of the general population (WHO
2019). The majority of people will respond well to conventional
antiepileptic drugs (AED (International League Against Epilepsy
1997)). However, around 30% will not achieve remission, de-
spite trying numerous antiepileptic drugs, often in combination
(Sander 1993; Schmidt 1995; Brodie 1996). In an attempt to im-
prove outcomes for these drug-resistant people, a number of newer
potential antiepileptic drugs have been assessed over the past 20
to 30 years. One such drug is sulthiame.
Description of the intervention
Sulthiame (also known as sultiame) is used widely as an antiepilep-
tic drug in some European countries and in Israel (Gross-Selbeck
2001; Koepp 2002; Engler 2003; Ben-Zeev 2004; Chahem 2007;
Swiderska 2011). It is usually taken in tablet form, with doses
taken two to three times per day. When used as monotherapy,
sulthiame has been reported to reduce the occurrence of seizures
and reduce electroencephalographic (EEG) discharges in people
with benign epilepsy of childhood with centrotemporal spikes
(Rating 2000; Bast 2003; Ben-Zeev 2004; Wirrell 2008), benign
focal epilepsy of childhood (Engler 2003; Ben-Zeev 2004), symp-
tomatic, localisation-related epilepsy, juvenile myoclonic epilepsy
(Ben-Zeev 2004), and adults with drug-resistant epilepsy and
learning disabilities (Koepp 2002). In addition, sulthiame as an
add-on therapy has been reported to reduce seizure activity in peo-
ple with drug-resistant epilepsy (Livingston 1967; Chahem 2007;
Miyajima 2009).
Reported adverse effects of sulthiame include: deterioration of
reading ability, memory, attention skills, and mathematical abil-
ity (Wirrell 2008), mixed respiratory and metabolic acidosis (a
condition characterised by an abnormally low arterial blood pH
(Weissbach 2010)), and crystalluria (the excretion of crystals in
the urine (Go 2005)).
How the intervention might work
Sulthiame is a sulphonamide, which may exert antiepileptic activ-
ity by producing a modest intracellular acidosis in central neurons
via its action as a carbonic anhydrase inhibitor, thereby reducing
the frequency of action potentials and epileptiform bursts (Leniger
2002).
Why it is important to do this review
A summary of the best available evidence about the efficacy and
tolerability of sulthiame as an add-on therapy for people with
epilepsy is required to inform the most appropriate clinical use of
this drug and to inform decisions about the further assessment of
this drug.
O B J E C T I V E S
To assess the efficacy and tolerability of sulthiame as add-on ther-
apy for people with epilepsy of any aetiology compared with
placebo or another antiepileptic drug.
M E T H O D S
Criteria for considering studies for this review
Types of studies
1. Randomised controlled trials (RCTs)
2. Double, single, or unblinded trials
3. Placebo-controlled trials
4. Parallel group or cross-over studies
Types of participants
1. Participants with drug-resistant epilepsy (defined as epilepsy
in which seizure control is not adequately managed with one or
more antiepileptic drugs)
2. Participants of any age
3. Participants with epilepsy of any aetiology
Types of interventions
1. For the active treatment group, sulthiame as an adjunct to
the participant’s AED regimen
2. For the control group, placebo or another AED added to
the participant’s AED regimen
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Types of outcome measures
Primary outcomes
1. 50% or greater reduction in seizure frequency. We selected
this outcome as it is commonly reported in studies assessing the
efficacy of AEDs.
Secondary outcomes
1. Complete cessation of seizures during follow-up
2. Mean seizure frequency
3. Time-to-treatment withdrawal; reflective of both
intolerable adverse effects and lack of efficacy
4. Any reported adverse effects, such as, but not limited to,
deterioration in cognitive ability, crystalluria, or respiratory and
metabolic acidosis
5. Quality of life; an overall improvement or deterioration
Search methods for identification of studies
Electronic searches
We ran searches for the original review in January 2012, and subse-
quent searches on 28 August 2012, 3 June 2014, 11 August 2015,
and 22 November 2017. For the latest update, we searched the
following databases on 17 January 2019:
1. The Cochrane Register of Studies (CRS Web; includes the
Cochrane Epilepsy Group Specialized Register and the Cochrane
Central Register of Controlled Trials (CENTRAL)), using the
search strategy outlined in Appendix 1;
2. MEDLINE Ovid (1946 to 16 January 2019), using the
search strategy outlined in Appendix 2;
3. ClinicalTrials.gov, using the search strategy outlined in
Appendix 3;
4. The WHO International Clinical Trials Registry Platform
(ICTRP), using the search strategy outlined in Appendix 4.
We also searched SCOPUS (1823 to 3 June 2014), as an alter-
native to Embase, using the search strategy outlined in Appendix
5, but this is no longer necessary, because randomised and quasi-
randomised controlled trials from Embase are now included in
CENTRAL.
We did not impose any language restrictions.
Searching other resources
We checked the reference lists of retrieved reports for additional
reports of relevant studies. We also contacted the manufacturers of
sulthiame for information about ongoing or unpublished studies.
Data collection and analysis
Selection of studies
Two review authors (RB and KMM) independently assessed stud-
ies for inclusion. They resolved disagreements by discussion.
Data extraction and management
We extracted data from the trial and assessed the design of the trial
and demographic makeup of the participants, in addition to the
outcomes listed in the Types of outcome measures section. Two
review authors (RB and KMM) independently assessed studies,
and resolved disagreements by discussion. The types of data ex-
tracted are listed below.
Trial design
1. Method of randomisation
2. Method of concealment
3. Duration of baseline period
4. Duration of treatment period
5. Duration of ’wash-out’ period for cross-over studies
6. Dose of sulthiame
7. Description of adverse effects
8. Description of withdrawals and drop-outs
Demographic information
1. Number of participants in treatment group
2. Number of participants in control group
3. Age
4. Sex
5. Type of seizures and epilepsy
6. Mean baseline seizures frequency
7. AED(s) on which participants were already established
Assessment of risk of bias in included studies
Two review authors (RB and KMM) independently assessed the
risk of bias associated with each study’s methodology, using the trial
design factors outlined in the Data extraction and management
section. Risk of bias was evaluated according to the Cochrane ’Risk
of bias’ tool, as detailed in the Cochrane Handbook for Systematic
Reviews of Interventions (Higgins 2011). The Cochrane ’Risk of
bias’ tool comprises seven parameters: (1) random sequence gen-
eration, (2) allocation concealment, (3) incomplete outcome data,
(4) selective reporting, (5) blinding of participants and personnel,
(6) blinding of outcome assessors, and (7) other bias. For each
entry, they awarded a judgement (low risk of bias, high risk of
bias, or unclear risk of bias), supported by an agreed review author
comment. They resolved disagreements by discussion.
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Measures of treatment effect
For binary data, we expressed relative treatment effects as risk
ratios (RR) with 95% confidence intervals (CI); for continuous
data, we had planned to use mean difference (MD) with 95% CI.
When we compared data where one group had zero events, we
calculated the RR by adding 0.5 to each value in the contingency
table, as advised in section 9.2.2.2 of Chapter 9 of the Cochrane
Handbook for Systematic Reviews of Interventions (Sterne 2011). We
considered that a P value of less than 0.05 demonstrated statistical
significance.
Unit of analysis issues
The inclusion of cross-over studies in meta-analyses introduces
unit of analysis issues because each participant contributes data to
both treatment groups. We had planned to extract data from the
first treatment period of any eligible cross-over study, had any been
identified. Essentially, we would have regarded the first treatment
period as a parallel study, thus preventing data from the same
participant from being considered twice, whilst simultaneously
avoiding any issues of carry-over effect.
We did not include any cross-over studies in this current update,
hence there were no unit of analysis issues.
Dealing with missing data
We performed intention-to-treat analysis, and assumed treatment
withdrawal to be due to either lack of efficacy or intolerable adverse
effects. We had planned to calculate any missing statistics from
the raw data where possible.
Assessment of heterogeneity
We had planned to assess methodological heterogeneity by com-
paring each trial for aspects outlined in the trial design section
of Data extraction and management. We had planned to assess
clinical heterogeneity by comparing each trial for aspects outlined
in the demographic information section of Data extraction and
management. We had planned to assess statistical heterogeneity
using the I² statistic, and the following parameters as a guideline:
• 0% to 40%: might not be important;
• 30% to 60%: may represent moderate heterogeneity;
• 50% to 90%: may represent substantial heterogeneity;
• 75% to 100%: represents considerable heterogeneity.
Assessment of reporting biases
We reported bias according to Chapter 10 of theCochrane Hand-
book for Systematic Reviews of Interventions (Sterne 2011). If we
had identified sufficient RCTs, we had planned to make a funnel
plot to help identify publication bias, and investigate any visual
asymmetry by exploratory analysis. We attempted to obtain source
data for any studies included in the analysis in order to assess any
non-reported outcomes.
Data synthesis
We had planned to analyse data in a meta-analysis using a fixed-
effect model in Review Manager 5 (RevMan 2014), provided this
was clinically appropriate, and provided that we found no substan-
tial heterogeneity. If we had found evidence of substantial hetero-
geneity, we would have explored the factors for heterogeneity. If
substantial heterogeneity could not be readily explained, we would
have used a random-effects model to perform meta-analysis. We
used an intention-to-treat approach for the primary analysis, in
which all participants were included in the treatment groups to
which they were allocated, regardless of whether or not they re-
ceived the treatment. A P value of < 0.05 qualified statistical sig-
nificance.
Subgroup analysis and investigation of heterogeneity
We had planned to assess the effects of sulthiame in participants
with focal epilepsy and participants with generalised epilepsy sep-
arately.
Sensitivity analysis
We had planned to assess the influence on results of studies of poor
methodological quality by undertaking analyses with and without
these studies.
Summarising and interpreting results
We used the GRADE approach, as outlined in the GRADE Hand-
book (Schünemann 2013), to interpret findings, and GRADEpro
GDT software (which imports data from Review Manager 5 soft-
ware (GRADEpro 2015)), to create a ’Summary of findings’ table
for the following outcomes: 50% or greater reduction in seizure
frequency, complete cessation of seizures during follow-up, mean
seizure frequency, time-to-treatment withdrawal, total number of
participants experiencing one or more adverse effects, total num-
ber of participants experiencing somnolence, and quality of life.
R E S U L T S
Description of studies
Results of the search
Figure 1 summarises the results of the searches and the process
of screening and selecting studies for inclusion in the review. Our
search identified a total of 107 papers and trials register records. We
removed 61 duplicate records, leaving 46 records to be screened.
After reviewing the titles and abstracts, we excluded 23 records as
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it was clear that they were not randomised controlled add-on stud-
ies comparing sulthiame (sultiame) with placebo or active control
in epilepsy. Further evaluation at the full-text stage of the remain-
ing items is presented below and in the tables Characteristics of
included studies and Characteristics of excluded studies.
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Figure 1. Study flow diagram
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Included studies
One study met our inclusion criteria (Debus 2004). It was a ran-
domised, double-blind, placebo-controlled, parallel group study.
Infants with newly diagnosed West syndrome, which had to in-
clude the features of infantile spasms, and either hypsarrhythmia or
hemihypsarrhythmia, were recruited into the study. Infants with a
history of epilepsy before the diagnosis of West syndrome were ex-
cluded, unless treated with phenytoin or phenobarbitone, both of
which are reported to be ineffective in West syndrome (Hrachovy
1991). Thirty-seven infants were included in the study; 20 re-
ceived sulthiame and 17 received placebo.
The text publication reported that the infants had a mean age of
7.7 months (range: 3.5 to 15 months). The author, however, pro-
vided previously unpublished data that conflicted with this. Dur-
ing correspondence, the author informed us that the intervention
group had consisted of 11 boys and nine girls, and that their mean
(range) age had been 7.5 months (two to 15 months). According
to the correspondence, the control group consisted of seven boys
and 10 girls and their mean age (range) was 6.1 months (three
to 13 months). Notably, the minimum age of infants for both
groups, provided during correspondence, was lower than the min-
imum age stated in the text publication (two months compared
3.5 months, respectively). We were unable to verify which mean
age and age range was correct.
The aetiological make up of the groups was: idiopathic cause -
four (20%) in the intervention group, three (18%) in the control
group; premature birth - five (25%) in the intervention group,
three (18%) in the control group; tuberous sclerosis - three (15%)
in the intervention group, four (24%) in the control group; mal-
formations - two (10%) in the intervention group, two (12%) in
the control group; birth asphyxia - two (10%) in the intervention
group, one (6%) in the control group; trisomy 21 - one (5%) in
the intervention group, one (6%) in the control group; congenital
heart defect - one (5%) in the intervention group, one (6%) in
the control group; porencephaly - none in the intervention group,
one (6%) in the control group; encephalopathy - none in the in-
tervention group, one (6%) in the control group; unclear - two
(10%) in the intervention group, none in the control group.
After three days of baseline pyridoxine (150 to 300 mg/kg/day),
the infants were randomised to receive sulthiame 5 mg/kg/day
or placebo. After a further three days, non-responders had the
dose of sulthiame or placebo doubled. At the end of day nine,
the study medication was disclosed following an electroencephalo-
graph, which had to include a period of sleep. Baseline seizure fre-
quency was not reported. The author of the study confirmed that
this was not measured because the positive endpoint of the study
was the absence of seizures, regardless of seizure frequency before
the start of the medication. The study does state that there was
no significant difference in baseline seizure frequency between the
intervention and control groups. As it was not possible to perform
a meta-analysis, we presented our findings as a narrative analysis.
This trial was funded by DESITIN Pharma, in Germany.
Excluded studies
We excluded a further 19 records at the full-text screening phase.
Amongst them were seven RCTs: six studied sulthiame as a
monotherapy in epilepsy (Li 2000; Rating 2000; Bast 2003;
Basnec 2005; ISRCTN66730162; Borggraefe 2013), and one
compared sulthiame with placebo as a monotherapy in healthy par-
ticipants with no history of epilepsy, measuring axonal excitabil-
ity of cortical neurons as a primary outcome (Siniatchkin 2006).
We excluded three studies as they were not RCTs (Ingram 1963;
Griffiths 1964; Livingston 1967), and another study was excluded
as it included participants with and without epilepsy (Moffat
1970). There were multiple references that were linked to single
studies, which accounts for the larger number of records compared
to the number of excluded studies. Please refer to Characteristics
of excluded studies for further details
Risk of bias in included studies
The rating for each domain and the respective reasoning can be
found in the ’Risk of bias’ table within the ’Characteristics of
included studies’ table, and is summarised in Figure 2.
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Figure 2. Risk of bias summary: review authors’ judgements about each risk of bias item for each included
study
Allocation
The Debus 2004 study stated that the infants were randomised
to either the intervention or control group, but did not report
the method of randomisation. When contacted, the author of
the study provided information about the previously unpublished
method of randomisation for the purpose of this Cochrane Re-
view. Infants were allocated a number between one and six after a
pharmacist had rolled a die. Odd numbers were assigned to sulthi-
ame, even numbers were assigned to placebo. We judged this to be
an adequate method for random sequence generation and awarded
low risk of bias.
The study author also provided previously unpublished details
regarding allocation concealment. Sealed envelopes with partici-
pant identification numbers written on the outside, and a letter
containing the allocation hidden on the inside, were sent by the
pharmacy with correspondingly numbered medication boxes. As
a result, allocation was effectively concealed, and we judged the
study to be at low risk of bias for allocation concealment.
Blinding
The study report stated that the treatment was started in a dou-
ble-blind fashion, but did not provide details of the method or
effectiveness of the blinding process beyond the description given
for allocation concealment. Without the use of identical tablets
for placebo and sulthiame, it is possible that the infants’ parents
or study personnel could have become aware of, or guessed the
infant’s group allocation. Therefore, it was unclear how blinding
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was maintained for the duration of the treatment period. Con-
sequently, we awarded unclear risk of bias for performance and
detection bias.
Incomplete outcome data
Four infants did not complete the study period. An intention-to-
treat analysis, including these infants, was reported, therefore we
awarded low risk of bias for attrition bias.
Selective reporting
The study report stated that four infants withdrew from the study
(three from the intervention group and one from the control
group). The time-to-treatment withdrawal for one infant in the
intervention group was reported as being day six, but no timing
was given for the remaining three infants. The study author pro-
vided previously unpublished data for two of these.
Adverse effects were also reported incompletely in this study. The
total number of infants experiencing adverse effects in each group
was reported (nine in the intervention group, nine in the control
group), in addition to the number of infants experiencing somno-
lence (four in the treatment group, one in the control group). The
remaining adverse effects (vomiting, restlessness, loss of appetite,
diarrhoea, and abdominal pain) were reported for their occurrence
in the study population as a whole, but the specific number of
infants in each group who experienced each of these adverse effects
was not reported. The author informed us that these data were
not recorded. For this reason, we judged that the study was at high
risk of reporting bias.
Other potential sources of bias
Other bias arose from the lack of baseline demographic data. Con-
sequently, we were unable to determine whether there were any
baseline imbalances between the two treatment groups. In addi-
tion, the author of the study gave us a contradictory statement re-
garding the baseline period, stating that seizure frequency was not
measured at baseline. However, the study publication reported that
there was no significant difference in baseline seizure frequency
between treatment groups. As a result, we awarded the study un-
clear risk of other bias.
Effects of interventions
See: Summary of findings for the main comparison Sulthiame
add-on compared to placebo for epilepsy (event)
The results are summarised in Summary of findings for the main
comparison.
A 50% or greater reduction in seizure frequency
No data were reported for the primary outcome.
Complete cessation of seizures during follow-up
The study reported that six infants in the intervention group and
none of the infants in the control group showed a complete re-
sponse, meaning cessation of infantile spasms and the disappear-
ance of hypsarrhythmia on EEG testing. The aetiology of the re-
sponding infants was: idiopathic aetiology (n = 3), premature birth
(n = 1), trisomy 21 (n = 1), and congenital heart defect (n = 1).
Overall, the risk ratio (RR) for sulthiame compared with placebo
was 11.14 (95% confidence interval (CI) 0.67 to 184.47; Analysis
1.1). Although the effect was statistically insignificant (P = 0.09),
the RR was notably very large.
Mean seizure frequency
No data were reported for this outcome.
Time-to-treatment withdrawal
The study reported that one infant was withdrawn from the inter-
vention group due to withdrawal of parental consent, precipitated
by excessive somnolence. The publication did not state when this
happened, however, the study author provided previously unpub-
lished data and specified that this withdrawal occurred on day six.
The study also reported that one infant was withdrawn from the
control group because they had erroneously and openly received
sulthiame during the study period, but did not report the time of
treatment withdrawal. When asked, the study author stated that
it was not clear when this occurred. It was also not clear whose
decision it was to withdraw this infant, the parent’s or the investi-
gator’s.
The study publication reported that a further two infants were
withdrawn from treatment, but did not report the reasons for this,
or the time of withdrawal. The study author provided previously
unpublished data which informed us that the infants had both
been allocated to the intervention group, and were withdrawn
from treatment on days five and six, both due to withdrawal of
parental consent. Overall, more infants were withdrawn from the
treatment with add-on sulthiame group compared to the add-on
placebo group.
Adverse effects
The study reported that a total of nine infants in the sulthiame
intervention group (45%), and nine infants in the placebo control
group (53%), experienced one or more adverse effects (RR 0.85,
95% CI 0.44 to 1.64; P = 0.63; Analysis 1.2). The study authors
reported somnolence in four (20%) of the infants in the interven-
tion group, and one (6%) of the infants in the control group (RR
3.40, 95% CI 0.42 to 27.59; P = 0.25; Analysis 1.3). The study
authors reported the remaining adverse effects, stating that they
were distributed equally amongst each group, without providing
specific figures. Across the study population there was vomiting in
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14 infants (38%), restlessness in six infants (16%), loss of appetite
in two infants (5.5%), diarrhoea in one infant (3%), and abdom-
inal pain in one infant (3%).
Quality of life
No data were reported for this outcome.
D I S C U S S I O N
Summary of main results
We included one trial in this review (Debus 2004). This trial
assessed the effect of sulthiame as an add-on therapy for West
syndrome, after a baseline treatment with pyridoxine for three
days. The inclusion criteria were infants with a new diagnosis of
West syndrome, exhibiting infantile spasms, and hypsarrhythmia
or hemihypsarrhythmia. The exclusion criteria were a prior diag-
nosis of epilepsy, unless treated with phenytoin or phenobarbi-
tone, however, it was not clear how many infants entered the trial
having been treated with either of these antiepileptic drugs, or
whether the dose was reduced or discontinued prior to the study.
The study recruited 37 infants, 20 in the intervention group and
17 in the control group. Six infants from the treatment group and
none from the control group became seizure-free during the study.
Although this outcome did suggest that add-on sulthiame is more
effective for seizure control, the outcome did not reach statistical
significance. Adverse effects were incompletely reported. Overall,
there was no significant difference between the total number of
adverse effects reported in each group, or the number of infants
experiencing somnolence in each group. Time-to-treatment with-
drawal was incompletely reported, and we could not conduct any
meaningful analysis on the data reported. No data were reported
for the outcomes: 50% or greater reduction in seizure frequency,
mean seizure frequency, or quality of life.
Notably, although no data were reported for the primary outcome,
50% or greater reduction in seizure frequency, as specified in the
review protocol, we did not have any concerns about the lack of
reporting. This outcome is not considered clinically meaningful
in West syndrome, and is subsequently not routinely reported in
these studies. Two of the five secondary outcomes , treatment with-
drawal and adverse effects, however, were incompletely reported
and provided more reason for concern. Specifically, the author
was unable to confirm the time to withdrawal for the placebo-
randomised infant. Additionally, the author could not provide any
further data regarding the incidence rate of adverse effects, stating
that the data had not been recorded. We therefore judged that,
overall, the risk of reporting bias was high in this study.
Further to this, the risk of bias for randomisation and allocation
concealment was unclear from the published details. The study
author, however, subsequently provided us with methodological
details that demonstrated adequate methods. We consequently
changed our judgement to low risk of selection bias. We did not
receive any more details regarding the methods of blinding, there-
fore, we continued to award unclear risk of bias. Similarly, we
judged that the study was at unclear risk of other bias due to the
limited baseline data. We did, however, rate that there was low
attrition bias due to the intention-to-treat population used.
The results of the study suggest that sulthiame, compared to
placebo, may increase the incidence of complete cessation of
seizures for infants with West syndrome when used as an add-on
therapy to pyridoxine, however, we are very uncertain about the
reliability of this finding. Due to the small sample size, short treat-
ment duration, and the significant risk of bias described above,
we have serious concerns about the certainty of the evidence pre-
sented. Notably, none of the reported outcomes reached statistical
significance. No conclusions can be drawn regarding the occur-
rence of individual adverse effects or quality of life, as these two
measures were either incompletely reported, or not reported at all.
Overall completeness and applicability of
evidence
We were unable to conduct a meta-analysis as originally intended,
due to the lack of eligible studies and the subsequent inclusion of a
single study. This meant that we could not conduct any subgroup
or sensitivity analyses either.
There were further limitations, specifically concerning the data
provided by the single included study. First, the study did not
report data for our primary outcome (50% or greater reduction in
seizure frequency), or for two of the planned secondary outcomes
(mean seizure frequency, and quality of life). As a result, we were
unable to reach any conclusions for these outcomes.
The second issue regards the generalisability of the data for the
outcomes that were reported. Most notably, the included study
only investigated the use of sulthiame in infants with West syn-
drome. As a result, the findings of this review are limited to this
specific type of epilepsy, and cannot be generalised to all epilepsy
syndromes. It is also important to note that the infants included
in the Debus 2004 study did not, by definition, have drug-resis-
tant epilepsy. In this study, sulthiame was used as an add-on to
pyridoxine, a form of Vitamin B6, not in addition to another anti-
epileptic drug. Hence, the review does provide some insight into
the use of sulthiame as an add-on therapy, but not in the context
of drug-resistant epilepsy. As a result, the findings of the review
might have limited applications in clinical practice.
All of the participants in the included study were younger than 15
months. We have no data concerning the effect of sulthiame in
older children or adults. Therefore, the review findings restricted
specifically to infants with West syndrome.
Moreover, the study comprised a very small sample size population
(37 infants) and is thus, likely to be statistically underpowered.
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Consequently, it is not appropriate to assume that the effect esti-
mated in this review will necessarily be generalisable to all infants
with West syndrome. Therefore, it is evident that the evidence for
this review is severely lacking in completeness.
Quality of the evidence
We judged the single study included in this review to be at high
risk of bias. This mainly resulted from the incomplete reporting
of several of the intended outcomes. The study publication lacked
methodological details, which the study author confirmed during
correspondence. However, the study author failed to provide de-
tails on the method by which blinding was achieved and main-
tained. Accordingly, we downgraded the certainty of evidence for
all outcomes once for risk of bias, and twice more due to the in-
sufficient number of events reported. This was largely as a conse-
quence of the small sample size. As a result, we GRADE-assessed
the evidence for all three reported outcomes as being of very low
certainty.
Potential biases in the review process
For the purposes of this review, we defined drug-resistant epilepsy
as epilepsy in which seizure control had not been adequately man-
aged by one or more antiepileptic drugs. The definition of drug-
resistant epilepsy used here is not consistent with that endorsed
by the International League Against Epilepsy (ILAE), which spec-
ifies that drug-resistant epilepsy should refer to the failure of ad-
equate trials of two tolerated and appropriately chosen and used
antiepileptic drug schedules (whether as monotherapies or in com-
bination) to achieve sustained seizure freedom (Kwan 2010).
Although currently, none of the studies screened satisfied either
definition of drug-resistant epilepsy, the definition used for the
purposes of this review should be reviewed before conducting fu-
ture updates, to ensure that it remains consistent with current
recommendations. Importantly, the definition of drug-resistant
epilepsy used here has direct implications for which studies are el-
igible for inclusion, and consequently, could alter the conclusions
reached.
Agreements and disagreements with other
studies or reviews
The conclusions of the present review update remain consis-
tent with the conclusions of the previously published versions
of this review, largely because we found no additional eligi-
ble studies (Milburn-McNulty 2011; Milburn-McNulty 2013;
Milburn-McNulty 2015). Independent of this review and the in-
cluded study, few reports exist regarding the use of sulthiame as an
add-on therapy. We were able to identify two retrospective stud-
ies, which despite being ineligible for this review, remain informa-
tive about sulthiame as an add-on therapy for epilepsy (Swiderska
2011; Caraballo 2018).
The most recent of the two studies investigated the use of add-
on sulthiame in participants, aged 4 to 16 years (mean age 9
years) with drug-resistant Lennox-Gastaut syndrome, a paediatric
epilepsy characterised by multiple seizure types (Caraballo 2018).
Eligible participants had failed treatment with four or more pre-
vious anti-epileptic drugs, prior to commencing treatment with
sulthiame. During the study, the medical records of 44 partici-
pants were reviewed and retrospectively analysed. Participants had
received sulthiame 5 to 30 mg/kg/day in addition to their current
anti-epileptic treatment (median two concomitant anti-epileptic
drugs), over a treatment period of 12 to 60 months (mean treat-
ment period 20 months). Twenty-seven of the 44 participants
(61%) involved in the study attained a 50% or greater reduction in
seizure frequency, one of whom was rendered seizure-free. Adverse
effects were reported by ten of the 44 participants and included:
hyperpnoea (n = 4), dyspnoea (n = 4), nausea (n = 1), drowsiness
(n = 1), headache (n = 4), decreased appetite (n = 2), allergic skin
rash (n = 2), and irritability (n = 2). The instances of hyperpnoea
and dyspnoea responded to adjustments in the dosage of sulthi-
ame. All reported adverse effects were mild and transient in na-
ture, and in none of the reported cases did adverse effects lead to
discontinuation of treatment.
The earlier study by Swiderska 2011 also reviewed the medical
records of paediatric participants (aged 2 to 17 years; mean age 10.7
years) with drug-resistant epilepsy (defined as people who failed
to respond to treatment with two or more previous anti-epileptic
drugs). The medical records of 20 participants were analysed as
part of the review. Participants received a median dose of sulthi-
ame 8.2 mg/kg/day in addition to their anti-epileptic drugs (range
1 to 3 anti-epileptic drugs; mean 1.2 anti-epileptic drugs) over a
treatment period ranging form two to 37 months (mean treatment
period 18 months). At three months, 14 of 20 participants (70%)
reported a 50% or greater reduction in seizure frequency, however,
at subsequent follow-up points (11, 18, and 20 months), only
four participants (20%) responded; three of whom were rendered
seizure-free. Seven participants reported one or more adverse ef-
fects, which included drowsiness (n = 2), cognitive slowing (n =
1), hypersalivation (n = 1), breathlessness (n = 1), tachypnoea (n =
1), and diarrhoea (n = 1). The adverse effects reported were largely
mild in severity and responsive to reductions in dosage. In only
two instances did participants withdraw from treatment as a result
of adverse effects (one due to cognitive impairment, and one due
to excessive drowsiness).
Both retrospective studies highlighted that sulthiame was effective
when used as an add-on treatment for epilepsy, similar to that im-
plied by the findings of this current review. Notably, the studies
evaluated the use of sulthiame over much longer treatment du-
rations than the treatment period used by Debus 2004 (6 days).
The efficacy noted after much longer treatment periods in these
retrospective studies suggests that the therapeutic effect, reported
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with regards to seizure freedom, within the short treatment period
used by Debus 2004, could potentially be maintained over much
longer treatment durations. The good tolerability profile of sulth-
iame was also emphasised by both retrospective studies, with the
majority of associated adverse effects being mild in severity. Cor-
respondingly, in this review, and as reported by Debus 2004, an
equal number of participants reported one or more adverse effects
in both the sulthiame add-on treatment group and in the placebo
group, implying that sulthiame is well-tolerated.
As a result, the conclusions of this review, which included data from
one randomised controlled trial, appear to be fairly consistent with
those of the retrospective studies, despite the significant differences
in methodology (Caraballo 2018; Swiderska 2011).
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
In people with West syndrome who have not received any anti-
epileptic drugs other than phenytoin or phenobarbitone, very low-
certainty evidence from one study suggests that sulthiame (sulth-
iame) may increase the likelihood of cessation of seizures and dis-
appearance of hypsarrhythmia when used as an add-on therapy
to pyridoxine, compared with placebo. However, the single study
was small, with a significant risk of bias, which greatly limits the
certainty of the evidence. No conclusions can be drawn about the
occurrence of adverse effects, change in quality of life, or mean
reduction in seizure frequency.
Implications for research
Several large, multi-centre, randomised controlled trials, compar-
ing sulthiame as an add-on therapy with placebo or other anti-
epileptic drugs, need to be conducted in order to adequately in-
form clinical practice. Ideally, the trials should include participants
of any age, and should assess the effects of add-on sulthiame in
a variety of epilepsy types. Baseline seizure frequency should be
reported in addition to seizure frequency at the conclusion of the
trial. Time-to-treatment withdrawal should be fully reported. In-
dividual adverse effects should be reported for the treatment and
the control group, and quality of life scores, validated for use in
epilepsy, should be measured into any future randomised con-
trolled trials.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Debus 2004
Methods Double-blind, randomised, placebo-controlled parallel study
Participants 37 participants (sulthiame: N = 20; placebo: N = 17)
Mean age (range): 7.7 months (3 to 15 months)
Type of epilepsy: West syndrome
Interventions All participants received PDX (150 to 300 mg/kg/day) only, during the first 3 days of
the study
On day 4, sulthiame 5 mg/kg/day was added to the intervention group, and placebo was
added to the control
On day 7, the dose of sulthiame and placebo were doubled in participants who had not
achieved complete cessation of seizures (’non-responders’)
Outcomes Complete cessation of seizure activity during 9-day study
Adverse effects for entire trial population
Adverse effects for entire population - somnolence
Notes Trial funded by DESITIN Pharma (Hamburg, Germany)
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
Low risk Randomisation by roll of dice.
Allocation concealment (selection bias) Low risk Allocation concealed in sealed envelope for
duration of study
Blinding of participants and personnel
(performance bias)
All outcomes
Unclear risk Method not stated.
Blinding of outcome assessment (detection
bias)
All outcomes
Unclear risk Method not stated.
Incomplete outcome data (attrition bias)
All outcomes
Low risk Intention-to-treat analysis performed.
Selective reporting (reporting bias) High risk Incomplete data reported for time to treat-
ment withdrawal and adverse effects
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Debus 2004 (Continued)
Other bias Unclear risk Baseline period was not defined. Limited
participant demographic data provided
PDX: pyridoxine
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Basnec 2005 Sulthiame used as monotherapy in intervention group
Bast 2003 Sulthiame used as monotherapy in intervention group
Borggraefe 2013 Sulthiame used as monotherapy in intervention group
Griffiths 1964 Not a randomised controlled trial
Ingram 1963 Not a randomised controlled trial
ISRCTN66730162 Sulthiame used as monotherapy in intervention group
Li 2000 Sulthiame used as monotherapy in intervention group
Livingston 1967 Not a randomised controlled trial
Moffat 1970 Study assessing the effects of sulthiame on aggressive behaviour in both epileptic and non-epileptic participants
Rating 2000 Sulthiame used as monotherapy in the intervention group
Siniatchkin 2006 Study on the effect of sulthiame as monotherapy on axonal excitability of cortical neurons in subjects with no
history of epilepsy
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D A T A A N D A N A L Y S E S
Comparison 1. Sulthiame add-on versus placebo
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Complete cessation of seizures 1 37 Risk Ratio (M-H, Fixed, 95% CI) 11.14 [0.67, 184.47]
2 Adverse effects - Total number of
participants experiencing one
or more adverse effects
1 37 Risk Ratio (M-H, Fixed, 95% CI) 0.85 [0.44, 1.64]
3 Adverse effects - Somnolence 1 37 Risk Ratio (M-H, Fixed, 95% CI) 3.4 [0.42, 27.59]
Analysis 1.1. Comparison 1 Sulthiame add-on versus placebo, Outcome 1 Complete cessation of seizures.
Review: Sulthiame add-on therapy for epilepsy
Comparison: 1 Sulthiame add-on versus placebo
Outcome: 1 Complete cessation of seizures
Study or subgroup Sulthiame Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Debus 2004 6/20 0/17 100.0 % 11.14 [ 0.67, 184.47 ]
Total (95% CI) 20 17 100.0 % 11.14 [ 0.67, 184.47 ]
Total events: 6 (Sulthiame), 0 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.68 (P = 0.092)
Test for subgroup differences: Not applicable
0.005 0.1 1 10 200
Favours placebo Favours sulthiame
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Analysis 1.2. Comparison 1 Sulthiame add-on versus placebo, Outcome 2 Adverse effects - Total number of
participants experiencing one or more adverse effects.
Review: Sulthiame add-on therapy for epilepsy
Comparison: 1 Sulthiame add-on versus placebo
Outcome: 2 Adverse effects - Total number of participants experiencing one or more adverse effects
Study or subgroup Sulthiame Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Debus 2004 9/20 9/17 100.0 % 0.85 [ 0.44, 1.64 ]
Total (95% CI) 20 17 100.0 % 0.85 [ 0.44, 1.64 ]
Total events: 9 (Sulthiame), 9 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 0.48 (P = 0.63)
Test for subgroup differences: Not applicable
0.005 0.1 1 10 200
Favours sulthiame Favours placebo
Analysis 1.3. Comparison 1 Sulthiame add-on versus placebo, Outcome 3 Adverse effects - Somnolence.
Review: Sulthiame add-on therapy for epilepsy
Comparison: 1 Sulthiame add-on versus placebo
Outcome: 3 Adverse effects - Somnolence
Study or subgroup Sulthiame Placebo Risk Ratio Weight Risk Ratio
n/N n/N M-H,Fixed,95% CI M-H,Fixed,95% CI
Debus 2004 4/20 1/17 100.0 % 3.40 [ 0.42, 27.59 ]
Total (95% CI) 20 17 100.0 % 3.40 [ 0.42, 27.59 ]
Total events: 4 (Sulthiame), 1 (Placebo)
Heterogeneity: not applicable
Test for overall effect: Z = 1.15 (P = 0.25)
Test for subgroup differences: Not applicable
0.005 0.1 1 10 200
Favours sulthiame Favours placebo
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A P P E N D I C E S
Appendix 1. Search strategy for CRS Web
1. (sulthiame OR sultiame OR Ospolot) AND CENTRAL:TARGET
2. MESH DESCRIPTOR Epilepsy EXPLODE ALL AND CENTRAL:TARGET
3. MESH DESCRIPTOR Seizures EXPLODE ALL AND CENTRAL:TARGET
4. (epilep* OR seizure* OR convuls*):AB,KW,MC,MH,TI AND CENTRAL:TARGET
5. #2 OR #3 OR #4 AND CENTRAL:TARGET
6. #1 AND #5
Appendix 2. Search strategy for MEDLINE Ovid
This strategy is based on the Cochrane highly sensitive search strategy for identifying randomised trials published in Lefebvre 2011.
1. (sulthiame or sultiame or Ospolot).tw.
2. exp Epilepsy/
3. exp Seizures/
4. (epilep$ or seizure$ or convuls$).tw.
5. 2 or 3 or 4
6. exp *Pre-Eclampsia/ or exp *Eclampsia/
7. 5 not 6
8. (randomized controlled trial or controlled clinical trial or pragmatic clinical trial).pt. or (randomi?ed or placebo or randomly).ab.
9. clinical trials as topic.sh.
10. trial.ti.
11. 8 or 9 or 10
12. exp animals/ not humans.sh.
13. 11 not 12
14. 1 and 7 and 13
15. remove duplicates from 14
Appendix 3. ClinicalTrials.gov search strategy
Interventional Studies | Epilepsy | sulthiame or sultiame or ospolot
Appendix 4. ICTRP search strategy
Condition: epilepsy
Intervention: sulthiame or sultiame or ospolot
Appendix 5. SCOPUS search strategy
(TITLE-ABS-KEY(sulthiame OR sultiame OR ospolot)) AND (((((TITLE-ABS-KEY(epilep* OR “infantile spasm” OR “ring chromo-
some 20” OR “R20” OR “myoclonic encephalopathy” OR “pyridoxine dependency”)) OR (TITLE-ABS-KEY(syndrome W/2 (aicardi
OR angelman OR doose OR dravet OR janz OR jeavons OR “landau kleffner” OR “lennox gastaut” OR ohtahara OR panayiotopoulos
OR rasmussen OR rett OR “sturge weber” OR tassinari OR “unverricht lundborg” OR west)))) OR (TITLE(seizure OR convuls*))) OR
((TITLE-ABS-KEY(lafora* W/4 (disease OR epilep*))) AND NOT (TITLE(dog OR canine) OR INDEXTERMS(dog OR canine))))
AND NOT (TITLE(*eclampsia) OR INDEXTERMS(*eclampsia)) AND NOT INDEX(medline)) AND (TITLE((randomiz* OR
randomis* OR controlled OR placebo OR blind* OR unblind* OR “parallel group” OR crossover OR “cross over” OR cluster OR
“head to head”) PRE/2 (trial OR method OR procedure OR study)) OR ABS((randomiz* OR randomis* OR controlled OR placebo
OR blind* OR unblind* OR “parallel group” OR crossover OR “cross over” OR cluster OR “head to head”) PRE/2 (trial OR method
OR procedure OR study)))
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W H A T ’ S N E W
Date Event Description
17 January 2019 New search has been performed Searches updated 17 January 2019; no new relevant
studies identified
17 January 2019 New citation required but conclusions have not changed Conclusions are unchanged
H I S T O R Y
Protocol first published: Issue 12, 2011
Review first published: Issue 3, 2013
Date Event Description
11 August 2015 New citation required but conclusions have not changed No new relevant studies, conclusions remain unchanged
11 August 2015 New search has been performed Searches updated 11 August 2015
C O N T R I B U T I O N S O F A U T H O R S
R Bresnahan: assessed trials for inclusion for the current review update, GRADE-assessed outcomes for the Summary of findings for
the main comparison, and composed the final document for the review update.
K Martin-McGill: assessed trials for inclusion for the current review update and GRADE-assessed outcomes for the Summary of
findings for the main comparison.
P Milburn-McNulty: systematic review of studies and composed final document for the original review (Milburn-McNulty 2013) and
the update published in 2015 (Milburn-McNulty 2015).
G Powell: systematic review of studies for the original review (Milburn-McNulty 2013) and the update published in 2015 (Milburn-
McNulty 2015).
G Sills: edited the final document for the original review (Milburn-McNulty 2013) and the update published in 2015 (Milburn-McNulty
2015).
A Marson: edited the final document for the original review (Milburn-McNulty 2013) and the update published in 2015 (Milburn-
McNulty 2015).
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D E C L A R A T I O N S O F I N T E R E S T
R Bresnahan: none known
K Martin-McGill: none known
P Milburn-McNulty: none known
G Powell: acted as a medical consultant for UCB to provide guidance on the development of a study protocol.
G Sills: In the 36 months preceding the previous review update (Milburn-McNulty 2015), Dr Graeme J Sills has received personal
financial support for consultancy and speaking engagements from a variety of pharmaceutical companies that market drugs for the
treatment of epilepsy.
A Marson: a consortium of pharmaceutical companies (GSK, EISAI, UCB Pharma) funded the National Audit of Seizure Management
in Hospitals (NASH) through grants paid to the University of Liverpool. Professor Tony Marson is part funded by National Institute
for Health Research Collaboration for Leadership in Applied Health Research and Care North West Coast (NIHR CLAHRC NWC).
S O U R C E S O F S U P P O R T
Internal sources
• No sources of support supplied
External sources
• National Institute of Health Research (NIHR), UK.
This review was supported by the National Institute for Health Research, via Cochrane Programme Grant funding to the Epilepsy
Group. The views and opinions expressed therein are those of the authors and do not necessarily reflect those of the Systematic
Reviews Programme, NIHR, NHS or the Department of Health.
D I F F E R E N C E S B E T W E E N P R O T O C O L A N D R E V I E W
Due to the presence of only one study, a meta-analysis was not possible. In addition, measurements of heterogeneity amongst studies
and sensitivity analysis were not possible.
Methods for dealing with unit of analysis issues and for the GRADE-assessment of evidence were added to the review, in accordance
with the latest standard methodological procedures expected by Cochrane, despite not being described in the original review protocol.
I N D E X T E R M S
Medical Subject Headings (MeSH)
Anticonvulsants [adverse effects; ∗therapeutic use]; Epilepsy [drug therapy]; Pyridoxine [therapeutic use]; Randomized Controlled
Trials as Topic; Spasms, Infantile [∗drug therapy]; Thiazines [adverse effects; ∗therapeutic use]
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MeSH check words
Female; Humans; Infant; Male
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